$15.19
-0.06-0.39%
At close: -
$15.34
0.150.99%
After Hours: Jun 18, 6:49 PM EDT
Comments
Loading...
Dr Reddy's Laboratories Analyst Ratings and Price Targets | NYSE:RDY | Benzinga
Dr Reddy's Laboratories Ltd has a consensus price target of $16.95 based on the ratings of 2 analysts. The high is $17 issued by Barclays on November 6, 2024. The low is $16.9 issued by HSBC on June 5, 2025. The 3 most-recent analyst ratings were released by HSBC, Barclays, and Barclays on June 5, 2025, November 6, 2024, and July 30, 2024, respectively. With an average price target of $40.3 between HSBC, Barclays, and Barclays, there's an implied 162.71% upside for Dr Reddy's Laboratories Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HSBC
Barclays
1calculated from analyst ratings
Analyst Ratings for Dr Reddy's Laboratories
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/05/2025 | Buy Now | 10.17% | HSBC | Damayanti Kerai 51% | $14.44 → $16.9 | Upgrade | Hold → Buy | Get Alert |
| 11/06/2024 | Buy Now | 10.82% | Barclays | Balaji Prasad55% | $17.4 → $17 | Maintains | Overweight | Get Alert |
| 07/30/2024 | Buy Now | 467.15% | Barclays | Balaji Prasad55% | $81 → $87 | Maintains | Overweight | Get Alert |
| 05/08/2024 | Buy Now | 428.03% | Barclays | Balaji Prasad55% | $80 → $81 | Maintains | Overweight | Get Alert |
| 01/29/2024 | Buy Now | 421.52% | Barclays | Balaji Prasad55% | $75 → $80 | Maintains | Overweight | Get Alert |
| 06/01/2023 | Buy Now | 356.33% | Barclays | Balaji Prasad55% | $67 → $70 | Maintains | Overweight | Get Alert |
| 10/31/2022 | Buy Now | 336.77% | Barclays | Balaji Prasad55% | $66 → $67 | Maintains | Overweight | Get Alert |
| 10/25/2022 | Buy Now | 330.25% | Barclays | Balaji Prasad55% | $69 → $66 | Maintains | Overweight | Get Alert |
| 09/12/2022 | Buy Now | 349.81% | Barclays | Balaji Prasad55% | $68 → $69 | Maintains | Overweight | Get Alert |
| 07/25/2022 | Buy Now | 343.29% | Barclays | Balaji Prasad55% | $70 → $68 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Dr Reddy's Laboratories (RDY) stock?
The latest price target for Dr Reddy's Laboratories (NYSE:RDY) was reported by HSBC on June 5, 2025. The analyst firm set a price target for $16.90 expecting RDY to rise to within 12 months (a possible 10.17% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dr Reddy's Laboratories (RDY)?
The latest analyst rating for Dr Reddy's Laboratories (NYSE:RDY) was provided by HSBC, and Dr Reddy's Laboratories upgraded their buy rating.
When was the last upgrade for Dr Reddy's Laboratories (RDY)?
The last upgrade for Dr Reddy's Laboratories Ltd happened on June 5, 2025 when HSBC raised their price target to $16.9. HSBC previously had a hold for Dr Reddy's Laboratories Ltd.
When was the last downgrade for Dr Reddy's Laboratories (RDY)?
There is no last downgrade for Dr Reddy's Laboratories.
When is the next analyst rating going to be posted or updated for Dr Reddy's Laboratories (RDY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dr Reddy's Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dr Reddy's Laboratories was filed on June 5, 2025 so you should expect the next rating to be made available sometime around June 5, 2026.
Is the Analyst Rating Dr Reddy's Laboratories (RDY) correct?
While ratings are subjective and will change, the latest Dr Reddy's Laboratories (RDY) rating was a upgraded with a price target of $14.44 to $16.90. The current price Dr Reddy's Laboratories (RDY) is trading at is $15.34, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
